CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present preclinical pharmacokinetic (PK) and pharmacodynamic (PD) data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference taking place October 26-30 in Philadelphia.
The new data will show the relationship between SY-1365’s PK and PD and its anti-tumor activity in mouse xenograft models of acute myeloid leukemia (AML) and triple negative breast cancer (TNBC).
Details on the presentations are as follows:
Date & Time: Sunday, October 29, from 12:30-4 p.m. ET
Presentation
Title: PK/PD Modeling of the First-in-Class, Potent and Selective
Covalent CDK7 Inhibitor, SY-1365, Provides Mechanistic Basis for
Intermittent Dosing Regimens in Preclinical Efficacy Models of
Hematologic and Solid Tumors
Session Title: Poster Session B
Session
Category: Therapeutic Agents: Small-Molecule Kinase Inhibitors
Presenter:
Kevin Sprott, Ph.D., Senior Director of Chemistry, Syros
Abstract
Number: B171
Location: Hall E, Pennsylvania Convention Center
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors, including transcriptionally dependent cancers such as triple
negative breast, small cell lung and ovarian cancers. Led by a team with
deep experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the therapeutic benefit of SY-1365 and
the benefits of Syros’ gene control platform. The words ‘‘anticipate,’’
‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’
‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results or events
could differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of various
important factors, including Syros’ ability to: advance the development
of its programs, including SY-1425 and SY-1365, under the timelines it
projects in current and future clinical trials; demonstrate in any
current and future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; replicate scientific and
non-clinical data in clinical trials; successfully develop a companion
diagnostic test to identify patients with the RARA and IRF8 biomarkers;
obtain and maintain patent protection for its drug candidates and the
freedom to operate under third party intellectual property; obtain and
maintain necessary regulatory approvals; identify, enter into and
maintain collaboration agreements with third parties; manage
competition; manage expenses; raise the substantial additional capital
needed to achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies; risks
described under the caption “Risk Factors” in Syros’ Quarterly Report on
Form 10-Q for the quarter ended June 30, 2017, which is on file with the
Securities and Exchange Commission; and risks described in other filings
that Syros makes with the Securities and Exchange Commission in the
future. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Syros expressly disclaims any
obligation to update any forward-looking statements, whether because of
new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016006109/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released October 16, 2017